Physician

David Thomas Wenk, M.D.

According to 2025 Medicare claims, David Wenk, M.D. (NPI: 1508087297) practices medical oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Pasco, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34655-1808.

Wenk's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 942 traditional Medicare patients, billed 285,300 HCPCS/CPT codes, and received $6,681,852 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,973 prescription claims across 414 beneficiaries totaling $3,283,264 in drug costs, led by Revlimid (Lenalidomide). DME data shows 49 claims. Open Payments data shows 89 records totaling $2,168. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,140,105 to $6,681,852. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,324,168 to $3,283,264. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,680 and ending at $3,970.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	775	262,730	$3,140,105
2016	758	321,463	$3,903,823
2017	866	371,399	$4,384,143
2018	991	466,031	$5,566,636
2019	1,048	482,456	$6,480,934
2020	855	507,264	$6,731,476
2021	926	442,820	$6,160,249
2022	989	458,056	$6,985,427
2023	922	396,349	$7,153,000
2024	942	285,300	$6,681,852

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	215	1,456	$1,324,168
2016	233	1,532	$1,394,960
2017	259	1,460	$2,111,166
2018	263	1,290	$1,139,931
2019	278	1,442	$2,898,783
2020	288	1,465	$4,280,950
2021	314	1,550	$5,165,298
2022	389	2,051	$6,103,568
2023	432	2,241	$5,101,842
2024	414	1,973	$3,283,264

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	79	$6,604
2016	N/R	83	$4,578
2017	N/R	N/R	N/R
2018	N/R	55	$3,218
2019	N/R	13	$713
2020	N/R	54	$3,620
2021	N/R	13	$243
2022	N/R	48	$2,725
2023	N/R	100	$17,175
2024	N/R	49	$2,269

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	531	2,069	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	422	825	$13
96372	Injection of drug or substance under skin or into muscle	224	1,048	$11
36415	Insertion of needle into vein for collection of blood sample	692	2,211	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	707	2,383	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	64	1,666	$959,759
Xtandi	Enzalutamide	20	600	$271,695
Jakafi	Ruxolitinib Phosphate	14	420	$237,363
Imbruvica	Ibrutinib	16	456	$212,452
Pomalyst	Pomalidomide	12	280	$201,833

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	23	$1,673
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$369
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	14	$227

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	89	$2,168	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Thomas Wenk, M.D.?

Tedicare shows public-source Medicare data for David Thomas Wenk, M.D. (NPI 1508087297), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Thomas Wenk, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David Thomas Wenk, M.D.?

David Thomas Wenk, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does David Thomas Wenk, M.D. have Open Payments data?

David Thomas Wenk, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.